COVID-19-induced acute renal tubular injury associated with elevation of serum inflammatory cytokine

Fukao, Yusuke; Nagasawa, Hiroki; Nihei, Yasunori; Hiki, Makoto; Naito, Toshio; Kihara, Masao; Gohda, Tomohito; Ueda, Seinosuke; Suzuki, Yusuke

doi:10.1007/s10157-021-02101-z

Cited by 20 publications

(25 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Novel urinary biomarkers have been proposed in COVID-19, including urine 11-dehydro-thromboxane B2, 8-hydroxy-2′-deoxyguanosine, and liver-type fatty acid binding protein (L-FABP) levels, all of which were higher in this patient cohort at the time of hospitalization ( 101 ). N-acetyl-β-D-glucosaminidase, β2-microglobulin, α1-microglobulin, and L-FABP, which are all markers of tubular injury, were significantly associated with inflammation, as were IL-6 levels ( 102 ). Indeed, another observational study confirmed the association between pro-inflammatory cytokines, urinary cytokines, and urinary kidney injury markers ( 103 ).…”

Section: Diagnostic and Prognostic Value Of Biomarkersmentioning

confidence: 99%

Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19

et al. 2022

View full text Add to dashboard Cite

Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) causes a wide spectrum of clinical manifestations, with progression to multiorgan failure in the most severe cases. Several biomarkers can be altered in coronavirus disease 2019 (COVID-19), and they can be associated with diagnosis, prognosis, and outcomes. The most used biomarkers in COVID-19 include several proinflammatory cytokines, neuron-specific enolase (NSE), lactate dehydrogenase (LDH), aspartate transaminase (AST), neutrophil count, neutrophils-to-lymphocytes ratio, troponins, creatine kinase (MB), myoglobin, D-dimer, brain natriuretic peptide (BNP), and its N-terminal pro-hormone (NT-proBNP). Some of these biomarkers can be readily used to predict disease severity, hospitalization, intensive care unit (ICU) admission, and mortality, while others, such as metabolomic and proteomic analysis, have not yet translated to clinical practice. This narrative review aims to identify laboratory biomarkers that have shown significant diagnostic and prognostic value for risk stratification in COVID-19 and discuss the possible clinical application of novel analytic strategies, like metabolomics and proteomics. Future research should focus on identifying a limited but essential number of laboratory biomarkers to easily predict prognosis and outcome in severe COVID-19.

show abstract

Section: Diagnostic and Prognostic Value Of Biomarkersmentioning

confidence: 99%

Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Clinical studies suggest that about 50% of patients with COVID-19 had proteinuria and hematuria, suggesting a possible glomerular injury [ 29 ]. Abnormal urine analysis was associated with increased inflammatory markers and could be used to predict the overall outcomes in these patients with COVID-19 [ 30 ]. cFSGS has emerged as a distinct pathology associated with SARS-CoV-2-infected patients with proteinuria [ 27 ].…”

Section: Epidemiology and Clinical Presentationsmentioning

confidence: 99%

Similarities and Differences between COVID-19-Associated Nephropathy and HIV-Associated Nephropathy

et al. 2021

View full text Add to dashboard Cite

Kidney disease is a major complication of viral infection, which can cause both acute and chronic kidney diseases via different mechanisms such as immune-mediated injury, kidney cell injury from a direct viral infection, systemic effects, and antiviral drug-induced nephrotoxicity. HIV-associated nephropathy (HIVAN), characterized by collapsing focal segmental glomerulosclerosis (cFSGS), has been described 2 decades ago as a major complication of acquired-immunodeficiency syndrome. The pathogenesis of HIVAN has been well studied, including viral entry, host response, and genetic factors. The incidence of this disease has been dramatically dropped with current antiretroviral therapy. In the recent severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic, acute kidney injury was also found to be a major complication in patients with (coronavirus disease) COVID-19. These patients also developed glomerular disease such as cFSGS in African Americans with apolipoprotein L1 risk alleles, similar to HIVAN. Whether SARS-CoV-2 can infect kidney cells locally remains controversial, but both local infection and systemic effects are likely involved in the pathogenesis of this disease. In this review, we present a comparison of the clinical presentations, pathological findings, disease mechanisms, and potential treatments between HIVAN and COVID-19. Leveraging the knowledge in HIVAN and experimental approaches used to study HIVAN will facilitate the exploration in the pathogenesis of COVID-19-associated kidney disease and improve our management of COVID-19 patients.

show abstract

“…Furthermore, we cannot discard subclinical tubular damage that might be present in patients with rising CK. The use of other specific tubular biomarkers in addition to serum creatinine could be helpful in future studies [ 27 ]. Likewise, the use of myoglobin and an increase in the number of kidney biopsies are needed to confirm our findings and conduct formal risk prediction analyses with new biomarkers.…”

Section: Discussionmentioning

confidence: 99%

Longitudinal Changes of Serum Creatine Kinase and Acute Kidney Injury among Patients with Severe COVID-19

Soto-Fajardo

Castillo-Avalos

Hernández‐Paredes

et al. 2022

International Journal of Nephrology

View full text Add to dashboard Cite

Background. Acute kidney injury (AKI) is a common complication of COVID-19. Several etiologies have been identified, including pigment deposition likely associated with myopathic damage. Nevertheless, the relationship between longitudinal creatine-kinase trends and renal outcomes is uncertain. Aim. To correlate longitudinal changes in serum creatine-kinase levels with hospital-acquired AKI (beyond 48 h of hospital admission) in severe COVID-19 patients. Methods. This is a retrospective cohort study, and creatine-kinase levels were assessed over time in 1551 hospitalized patients with normal renal function at the time of hospital admission. Results. In subjects who developed hospital-acquired AKI (n = 126, 8.1%), the serum creatine-kinase concentration before AKI onset was not different when compared to patients without AKI (slope of log creatine-kinase/day = −0.09 [95% CI −0.17 to +0.19] vs. +0.03 [95% CI −0.1 to +0.1]). After AKI diagnosis, serum creatine-kinase levels showed a significantly ascendent slope (slope of log creatine-kinase/day after AKI diagnosis = +0.14; 95% CI + 0.05 to +0.3). The AKI evolution was the main factor associated with the creatine-kinase trend. Subjects with persistent AKI (n = 40, 32%) had rising creatine-kinase levels during hospitalization (slope of log creatine-kinase/day = +0.30 95% CI + 0.19 to +0.51). A rising creatine-kinase trend (n = 114, 8%) was associated with a 1.89-fold higher risk of in-hospital death (95% CI 1.14 to 3.16). Nevertheless, this association disappeared after adjusting AKI evolution and LDH baseline levels. Conclusion. In severe COVID-19 patients, a slight increase in creatine-kinase levels was observed after AKI occurrence but not before. Our results show that, at least for the appearance of hospital-acquired AKI, the CK rise does not meet the temporality criterion of causality regarding the occurrence of AKI. Rising creatine-kinase trends were associated with a higher risk of mortality, but this association was modified by AKI evolution and inflammation. There is a limited efficiency for AKI prognosis in the serial follow-up of CK levels in severe COVID-19 patients with normal renal function.

show abstract

COVID-19-induced acute renal tubular injury associated with elevation of serum inflammatory cytokine

Cited by 20 publications

References 23 publications

Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19

Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19

Similarities and Differences between COVID-19-Associated Nephropathy and HIV-Associated Nephropathy

Longitudinal Changes of Serum Creatine Kinase and Acute Kidney Injury among Patients with Severe COVID-19

Contact Info

Product

Resources

About